{
  "abstract": "Introduction: Data on bulking agents for stress urinary incontinence (SUI) in neurogenic patients remain limited, especially regarding polyacrylamide hydrogel (PAHG, Bulkamid®), now commonly used. This study evaluates the efficacy, safety, and tolerability of Bulkamid® in neurogenic women with SUI.Methods: From January 2020 to January 2025, we prospectively analyzed women undergoing periurethral Bulkamid® injections at a single center. Outcomes in neurogenic patients were compared to those without neurological disease. All procedures were performed outpatient under local anesthesia.Results: Fifteen neurogenic and 91 non-neurogenic women underwent treatment. Among neurogenic patients, 73.3% (11/15) reported improvement at 3 months (PGI-I). Four experienced transient acute urinary retention (27%). Self-catheterization was required in 3 patients; 2 remained unchanged post-procedure, and 1 improved. After a median 7-month follow-up, 66.7% of neurogenic patients remained dry or showed improvement. Complication rates were comparable between groups (20% vs. 27%, p=0.50). Treatment efficacy at 3 months was also similar (66.7% neurogenic vs. 63.3% non-neurogenic improved or very much improved; p=0.88).Conclusion: Bulkamid® shows comparable safety and efficacy in neurogenic and non-neurogenic women with SUI. However, benefits in patients performing self-catheterization remain uncertain and warrant further investigation.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "name": "Mélanie Lepretre"
    },
    {
      "name": "Brice Faurie"
    },
    {
      "name": "Camille Haudebert"
    },
    {
      "name": "Claire Richard"
    },
    {
      "name": "Alexandre Dubois"
    },
    {
      "name": "Amaury Facque"
    },
    {
      "name": "Juliette Hascoet"
    },
    {
      "name": "Benoît Peyronnet"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/54d4af9qgwhtx.bib",
  "cited_by": 1,
  "doi": "10.1016/j.fjurol.2026.103097",
  "fulltext_url": null,
  "id": "54d4af9qgwhtx",
  "issns": [
    "2950-4201",
    "2950-3930"
  ],
  "landing_url": "https://hal.science/hal-05586017v1",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2745|Pelvic floor disorders treatments"
    ]
  ],
  "openalex": "W7135038843",
  "pdf_url": "https://hal.science/hal-05586017/document",
  "pmcid": null,
  "pmid": "41831723",
  "published": "2026-09-01",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/54d4af9qgwhtx.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:24Z",
      "native_id": "hal-05586017",
      "source": "hal",
      "url": "https://hal.science/hal-05586017v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    }
  ],
  "title": "Periurethral injection of Bulkamid® for neurogenic vs. nonneurogenic female patients with stress urinary incontinence",
  "title_text": "Periurethral injection of Bulkamid® for neurogenic vs. nonneurogenic female patients with stress urinary incontinence",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:24Z",
  "url": "https://research.draconitic.com/paper/54d4af9qgwhtx",
  "venue": "The French Journal of Urology",
  "versions": []
}